| Name | Title | Contact Details |
|---|
Medavie EMS is a health care delivery and management company based in Dartmouth, Nova Scotia, Canada. We have a team of management staff that specializes in the areas of project management, planning, education, human resources, communications finance, physical resources, process design, facilitation, reporting, and information technology. Currently, Medavie EMS is responsible to deliver EMS in Nova Scotia, New Brunswick, Prince Edward Island, the District Municipality of Muskoka in Ontario, the Municipality of Chatham-Kent in Ontario, Elgin County in Ontario, Saskatoon and surrounding areas in Saskatchewan, as well as, communities across eastern Alberta. Each of these systems is managed by subsidiary companies which have established contracts with governments (provincial and municipal) or health authorities. In addition, Medavie EMS operates a patient transfer service in Massachusetts headquartered in Boston. Combined these companies directly employ or manage a total staff of approximately 3800, 550 of whom are in the US.
Dfh is a Hiawatha, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Hyer Medical, LLC is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Interstate Blood Bank Inc is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.